Latest Content

Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.

A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.

David T. Plante, MD, PhD, explains that separating mood-related sleepiness from primary hypersomnia relies on the course of illness and sleep testing.

Six studies found liver transplant disparities by insurance, region, ethnicity, and sex, plus links between unmet social needs and frailty in cirrhosis.

The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure and waist size.

Health systems are using pharmacist-run titration clinics, auto-consult triggers, and discharge follow-up to close gaps in HFpEF and HFmrEF care.

Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.